{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-316919","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.115260+00:00","generated_at":"2026-06-28T14:49:10.554174+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cerus Q3 product revenue $36.1M (+53% YoY); raises FY21 guidance to $127-129M","bullets":["Total revenue $42.1M (+44% YoY); product revenue $36.1M (+53% YoY) driven by U.S. INTERCEPT platelet adoption.","Net loss $12.4M ($0.07/shr) improved from $14.1M ($0.08/shr) in Q3 2020.","Product gross margin 51.3% vs 53.6% YoY; gross profit record $18.5M.","FY21 product revenue guidance raised to $127-129M (from $118-122M), representing 38-40% growth.","Cash and short-term investments $120.0M at Sept 30; $55M notes due, $10M revolver drawn."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-316919","json":"https://secwatch.observer/filing/0001193125-21-316919.json","markdown":"https://secwatch.observer/filing/0001193125-21-316919.md","text":"https://secwatch.observer/filing/0001193125-21-316919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000119312521316919/0001193125-21-316919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000119312521316919/d220853d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:49:10.554174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}